These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20399954)

  • 1. ORTHO EVRA and venous thromboembolism: an update.
    Jick SS; Hagberg KW; Kaye JA
    Contraception; 2010 May; 81(5):452-3. PubMed ID: 20399954
    [No Abstract]   [Full Text] [Related]  

  • 2. Evra contraceptive patch: risks of thromboembolism.
    Prescrire Int; 2007 Jun; 16(89):113-4. PubMed ID: 17590909
    [No Abstract]   [Full Text] [Related]  

  • 3. Allergic contact dermatitis due to transdermal contraception patch.
    Stricker T; Sennhauser FH
    J Pediatr; 2006 Jun; 148(6):845. PubMed ID: 16769403
    [No Abstract]   [Full Text] [Related]  

  • 4. [Systemic photosensibility and contraception].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2011; 138(4):367-8. PubMed ID: 21497270
    [No Abstract]   [Full Text] [Related]  

  • 5. Newer non-oral hormonal contraception.
    Bateson D; McNamee K; Briggs P
    BMJ; 2013 Feb; 346():f341. PubMed ID: 23412438
    [No Abstract]   [Full Text] [Related]  

  • 6. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users.
    Bodner K; Bodner-Adler B; Grünberger W
    Arch Gynecol Obstet; 2011 Mar; 283(3):525-30. PubMed ID: 20111970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormonal contraceptive patch].
    Lidegaard O
    Ugeskr Laeger; 2004 Oct; 166(41):3591. PubMed ID: 15515462
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.
    Dore DD; Norman H; Loughlin J; Seeger JD
    Contraception; 2010 May; 81(5):408-13. PubMed ID: 20399947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Another flawed database study.
    Szarewski A; Mansour D; Shapiro S
    Contraception; 2013 Apr; 87(4):505-6. PubMed ID: 23261232
    [No Abstract]   [Full Text] [Related]  

  • 12. Less estrogen in new oral contraceptive.
    Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
    [No Abstract]   [Full Text] [Related]  

  • 13. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
    Jick SS; Hagberg KW; Hernandez RK; Kaye JA
    Contraception; 2010 Jan; 81(1):16-21. PubMed ID: 20004268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Brenner P
    Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in hormonal contraception.
    Gupta N
    Adolesc Med Clin; 2006 Oct; 17(3):653-71; abstract xi. PubMed ID: 17030284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra).
    Zieman M
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S1-2. PubMed ID: 11849629
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norelgestromin/ethinyl estradiol transdermal system.
    Taneepanichskul S
    J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S82-4. PubMed ID: 17722322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone accretion in adolescents using the combined estrogen and progestin transdermal contraceptive method Ortho Evra: a pilot study.
    Harel Z; Riggs S; Vaz R; Flanagan P; Harel D; Machan JT
    J Pediatr Adolesc Gynecol; 2010 Feb; 23(1):23-31. PubMed ID: 19647454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.